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Abstract
Background: Drug repositioning is designed to discover new uses of known
drugs, which is an important and efficient method of drug discovery. Researchers
only use one certain type of Collaborative Filtering (CF) models for drug
repositioning currently, like the neighborhood based approaches which are good
at mining the local information contained in few strong drug-disease associations,
or the latent factor based models which are effectively capture the global
information shared by a majority of drug-disease associations. Few researchers
have combined these two types of CF models to derive a hybrid model with the
advantages of both of them. Besides, the cold start problem has always been a
major challenge in the field of computational drug repositioning, which restricts
the inference ability of relevant models.
Results: Inspired by the memory network, we propose the Hybrid Attentional
Memory Network (HAMN) model, a deep architecture combines two classes of
CF model in a nonlinear manner. Firstly, the memory unit and the attention
mechanism are combined to generate the neighborhood contribution
representation to capture the local structure of few strong drug-disease
associations. Then a variant version of the autoencoder is used to extract the
latent factor of drugs and diseases to capture the overall information shared by a
majority of drug-disease associations. In that process, ancillary information of
drugs and diseases can help to alleviate the cold start problem. Finally, in the
prediction stage, the neighborhood contribution representation is combined with
the drug latent factor and disease latent factor to produce the predicted value.
Comprehensive experimental results on two real data sets show that our proposed
HAMN model is superior to other comparison models according to the AUC,
AUPR and HR indicators.
Conclusions: Through the performance on two real-world data sets, we believe
that the proposed model can effectively alleviate the cold start problem in the
field of drug repositioning and give pharmaceutical personnel a new perspective
to develop new drugs.
Keywords: Drug repositioning; Data mining; Memory network; Attention
mechanism
1.Background
Drug repositioning is intended to discover new uses of drugs that have been ap-
proved by drug regulatory authorities [1]. This technology has played a major role
in drug discovery because traditional new drug development is a time-consuming,
costly, and unstable process that takes 10-15 years and costs 0.8-1 billion dol-
lars [2–4]. Compared with the traditional new drug development process, the ap-
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proved drugs have undergone several rigorous clinical trials, and their toxic and side
effects have been strictly evaluated [5]. Hence, drug repositioning technology can
shorten the drug development cycle to 6.5 years, research and development funding
could be reduced to 3 million dollars [6,7], and the related drugs are easier to pass
the regulatory review [8].
In recent years, benefited from the success of the CF (Collaborative Filtering)
model in the field of recommendation systems [9–11], more and more researchers
have applied the CF model to the field of drug repositioning. In general, the com-
putational methods of drug repositioning can be categorized into two main groups.
One is neighborhood based models [12–14] and the other is latent factor based
models [15–18].
Neighborhood based models recommends potential targets for drugs by identify-
ing neighborhoods of similar drugs or diseases based on the previous associations.
A computational framework has been suggested by Wang et al. [12], HGBI, a het-
erogeneous drug-target graph that includes known drug-target interactions as well
as similarities between drug-drug and target-target. A novel graph-based inferenc-
ing technique is implemented based on this graph to recommend potential targets
to drugs. Martinez et al. [13] created a drug-disease priority-setting methodology
called DrugNet based on ProphNet, a network-based priority-setting technique.
DrugNet model establishes a network of interconnected medicines, proteins and
illnesses and recognizes new associations of drug-disease by disseminating data in
the heterogeneous network above. Based on the theory that comparable drugs are
usually associated with comparable illnesses, Luo et al. [14] suggested a novel com-
putational technique called MBiRW, using some extensive similarity measures and
Bi-Random Walk (BiRW) to detect prospective novel signs for the specified drug.
Latent factor based models, which project each drug and disease into a common
low dimensional space to capture latent associations. Gottlieb et al. [15] suggested
a model called PREDICT, which calculates the connection between future drugs
and illnesses, primarily by incorporating the similarities between different drugs
and illnesses and using these characteristics to acquire fresh prospective character-
istics through a logical classifier. Luo et al. [16] build a heterogeneous drug-disease
interaction system by incorporating drug-drug, disease-disease, and drug-disease
networks denoted with a vast adjacency matrix for drug-disease, then implement
a Singular Value Thresholding algorithm to finish the adjacency matrix for drug-
disease with expected results for unidentified drug-disease pairs. In order to balance
the calculation error between the drug similarity and the disease similarity, Yang
et al. [17] proposed BNNR model, which incorporates the regularization of nuclear
specifications into the matrix decomposition model, and can effectively solve the
problem of overfitting and improve the prediction accuracy of the model. Yang et
al. [18] proposed the additional neural matrix factorization (ANMF) model, using
the auxiliary information of drugs or diseases to overcome the problem of data spar-
sity and introducing the neural network so that the ANMF model can capture the
nonlinear relationship between drugs and diseases.
However, the above researches were only based on one certain type of CF model to
solve the problem of drug repositioning, which leads to the following defects. Neigh-
borhood based methods capture local structure but usually ignore the majority of
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scores available owing to choosing from the junction of feedback between two drugs
or diseases at most K observations. In contrast, models of latent factor capture the
general global structure of the interactions between drugs and diseases, but often
overlook the existence of some powerful associations. At the same time, a specific
drug usually treats a smaller number of diseases to make the drug-disease corre-
lation matrix relatively sparse. Hence relying solely on sparse data of drug-disease
association can easily lead to cold start problems.
In recent years, due to the nonlinear fitting ability and excellent performance
in mining effective hidden features from raw data, deep learning has achieved re-
markable success in many fields. The memory network has achieved great achieve-
ment in the field of machine translation for its long-term and short-term memories
of historical information. Hence, inspired by deep learning and the memory net-
work [11, 19, 20], we propose the Hybrid Attentional Memory Network (HAMN), a
hybrid unified model that combines the advantages of both types of CF models. At
the same time, the drug-disease auxiliary information is used to alleviate the cold
start problem to some extent.
In the HAMN model, we combine the attention mechanism with memory unit
[21] to generate the neighborhood representation that captures the higher-order
complex associations between drugs and diseases. Memory unit allows encoding
of rich feature representations, while attention mechanisms can assign influential
neighbors greater weight. Next, a variant version of the autoencoder is used to
extract the valid latent factor of drug and disease and reduce the side effects of
cold-starting problem by combining drug similarity, disease similarity with drug-
disease associations. Finally, a nonlinear interaction between the local neighborhood
representation and the global latent factors derives the predicted value.
Our main contributions can be summarized as follows:
(1) We propose the HAMN model, a new network framework that combines neigh-
borhood based method with latent factor based model by the memory network, to
capture both the global structural information of drug-disease associations and the
local information contained in some strong drug-disease associations.
(2) We introduce drug-drug similarity and disease-disease similarity information
to overcome cold start problems. The experimental results show that this strategy
can alleviate the cold start problem to a certain extent. And the performance is
significantly improved in the new drug scenario.
(3) The HAMN model has been systematically tested in two real data sets, Got-
tlieb dataset and Cdataset [16]. The experimental results show that the performance
of our proposed HAMN model exceeds the state-of-the-art according to the AUC,
AUPR or HR indicators.
The rest of this paper is as constructed as follows: we will introduce the imple-
mentation details and principles of the HAMN model in section 2. In section 3,
the experiments and results of the HAMN model on the Gottlieb dataset and the
Cdataset will be discussed. The final section will serve as a summary of our work
and a guideline for future ventures.
2.Methods
The overall architecture of our proposed Hybrid Attentional Memory Network
(HAMN) model is shown in Figure 1. At a high level, the HAMN model consists
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of three modules, which in turn are the neighborhood contribution representation
module, the mining latent factor module, and the predictive value generation mod-
ule. Firstly, the neighborhood contribution representation module for capturing the
local information contained in few strong drug-disease associations. The module de-
rives the neighborhood contribution representation by combining the memory unit
and the attention weight mechanism, which will be described in detail in section
2.1.
Next, the mining latent factor module, which is used to capture the global informa-
tion of drug-disease associations. The module uses a variant version of autoencoder
to combine drug-disease relationships, drug similarity with disease similarity for the
extraction of drug latent factor or disease latent factors will be described in detail
in Section 2.2.
Finally, the predictive value generation module, which uses nonlinear function
to calculate the predicted value by combining the latent factor of drug, the latent
factor of disease and the neighborhood representation, will be described in detail
in Section 2.3. At the end of this section, we will derive the general loss function of
the HAMN model and the learning of the corresponding parameters.
Figure 1: The architecture of the HAMN model.
2.1 Neighborhood contribution representation
In order to capture the local information contained in some strong drug-disease
associations, inspired by [20], we first define the latent factor of drug called drugi,
where drugi ∈ R1×d is generated by a set of parameter vectors, d is the dimension
of latent factor, which stores the characteristic information of the drug. And defined
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the latent factor of disease called diseasej , where diseasej ∈ R1×d is generated by
another set of parameter vectors, which stores the specific preferences of the disease.
Next we define the drug preference vector pij as shown in equation (1), where each
dimension pijn represents the degree of similarity between the target drug i and its
neighbor drug n.
pijn = drug
T
i drugn ∀n ∈ N (i) (1)
Where N (i) represents the collection of drugs that are associated with disease
j. The intuition of our design formula (1) is as follows, the degree of compatibility
between the target drug i and the neighbor drug n is calculated by performing the
inner product operation of both the latent factor of drug i and the latent factor of
the neighbor drug n. The inner product operation enables the neighborhood drug
similar to the target drug i to achieve a larger compatible value, and vice versa.
According to the hypothesis that similar drugs can treat similar diseases, when
drug i infer whether it can treat the disease j, more similar neighbor drugs con-
tribute more to the decisions. Hence, by formula (2) normalizing the drug preference
vector pij , the attention weight of the target drug qij can be obtained. This atten-
tion weight is used to infer the contribution weight of the neighboring drugs. It
works because the attention weight vector qij can impose higher weights on similar
drugs in neighbors, while reducing the importance of less similar drugs, hence the
target drug i focuses on the influential subset of drugs in the neighborhood when
making decisions.
qijn =
exp(pijn)∑
k∈N(i) exp(pijn)
(2)
In order to learn the local information contained in few strong drug-disease as-
sociations, inspired by the memory network and the hypothesis which the local
structural information contained in the strong association is usually provided by
the neighbor of the target drug, hence the HAMN model uses an external memory
unit to store the characteristic information of the drug in the role of neighbor to
serve as the local structural information contained in the strong drug-disease asso-
ciations. Then use the attention weight vector qij accumulating the neighborhood
information contained in all the neighbor drugs of the target drug to obtain the
final neighborhood contribution representation. The generation method is shown in
formula (3).
oij =
∑
n∈N(j)
qijncn (3)
cn is another embedding vector of drug n, which is called external memory in the
original memory network framework. The external memory allows the storage of
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long-term information pertaining specifically to each drug’s role in the neighbor-
hood. Its essence is a set of parameter vectors, which can be represented by vectors
cn = [m1,m2, ...ml], where ml represents the parameters that can be learned dur-
ing model training. In other words, the attention mechanism selectively weights
the neighbors according to the specific drug and disease. The external memory
unit cn stores the local structural information contained in the strong drug-disease
associations. Then the neighborhood contribution representation generated by ac-
cumulating the sum of the attention vector and the memory unit cn, which can
make the contribution value of the influential neighbor greater and can capture
local structural information contained in the strong drug-disease association.
It is worth noting that the dimension of the external memory unit does not need
to be consistent with the dimension of the hidden feature vector of the drug. By
adjusting the dimension of the external memory unit, it can meet different scales of
computing drug repositioning data sets, which enhances the scalability of the model
to a certain extent. In the experimental section 3.3.1, the effect of external memory
unit dimension on model performance will be discussed.
2.2 Mining the latent factor of drugs and diseases
Both drugi and diseasej in section 2.1 are represented by parameter vectors,
which required a large amount of historical drug-disease correlation data to en-
sure the convergence and validity of that model parameters. However, the data of
computational drug repositioning is generally sparse and cannot meet the training
requirements of the above parameter vectors. At the same time, the cold start prob-
lem is a major challenge in the field of computational drug repositioning. In order
to extract effective latent factor and alleviate cold start problems, this section use
a variant version of autoencoder to extract the latent factor of drugs and diseases
instead of the above, and combine drug similarity and disease similarity at the same
time.
The bottom of Figure 1 shows the process of mining the latent factor of drug i
and disease j. We focus on the process of mining the latent factor of drug i, because
the process of mining the latent factor of disease j is theoretically the same.
R stands for the drug-disease associations matrix, where sdrugi = {Ri1, Ri2, ...Rin}
represents the associations between drug i and all diseases in the data set.
DrugSim stands for the drugs-drugs similarity matrix, where DrugSimi∗ =
[DrugSimi1, DrugSimi2, ..., DrugSimim] represents the similarity between drug i
and m drugs in the data set. To enhance the robustness of the input data, random
noise is added to sdrugi and DrugSimi∗ to generate s˜
drug
i and D˜rugSimi∗. Then we
perform the following encoding and decoding operations on the above two inputs
to extract the latent factor of the drug i, drugi.
drugi = g
(
W1s˜
drug
i + V1D˜rugSimi∗ + bd
)
(4)
sˆdrugi = f (W2drugi + bs) (5)
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DˆrugSimi∗ = f (V2drugi + bD) (6)
Equation (4) is the encoding operation, and equations (5) and (6) are the decoding
operations, where drugi represents the latent factor of the drug i. g and f represent
any activation function, W and V represent weight parameters, and b represents
bias parameters.
The loss caused by the above encoding and decoding operations includes the
error between all inputs and their reconstructed values, and the loss function is as
shown in equation (7), where ‖ sdrugi − sˆdrugi ‖2 and ‖ DrugSimi∗ − DˆrugSimi∗ ‖2
represent the error caused by the input value and the reconstructed value, and
‖ Wl ‖2 + ‖ Vl ‖2 controls the complexity of the model, which makes the model
have better generalization ability. α represents the equalization parameter and λ
represents the regularization parameter.
arg min
{Wl},{Vl},{bl}
α ‖ sdrugi − sˆdrugi ‖2 + (1− α) ‖ DrugSimi∗ − DˆrugSimi∗ ‖2
+ λ(
∑
l
‖Wl ‖2 + ‖ Vl ‖2) (7)
The latent factor of the drug i can be obtained by minimizing formula (7). Simi-
larly, the process of obtaining the latent factor of the disease j is theoretically the
same as the process of extracting the latent factor of the drug. The difference is
that sdiseasej and the diseases-diseases similarity matrix are used as inputs, where
sdiseasej = {R1j , R2j , · · ·Rmj} represents the vector of relationships between the
disease j and all drugs in the data set.
2.3 Predictive value generation
As mentioned above, the neighborhood based model captures the information
contained in few strong drug-disease associations and the latent factor model cap-
tures the global structural information of drug-disease associations. Therefore, we
used oij to capture the local information of the drugs-diseases relationships, and
used drugi and diseasej to capture the global information of the drugs-diseases re-
lationships, which are finally nonlinearly integrated by using the following formula
(8).
rˆij = Fout
(
ηhT (drugi  diseasej) + (1− η)WT oij + b
)
(8)
drugi and diseasej represent the latent factors of drugs and diseases calculated by
the HAMN model,  represents elementwise product, and oij represents neighbor
contribution representation. h and W represent the weight parameters, η is the
balance parameter, which controls the weight of the latent factor model and the
neighbor model in the final output. b represents the offset parameter, Fout represents
any activation function, and rˆij represents the predicted value.
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Where hT (drugi  diseasej) represents the output value of the latent factor
model, WT oij represents the output value of the neighbor model, and equation
(8) smooths the nonlinear integration of the two to obtain the predicted value.
The above operation enables the HAMN model to capture both global and local
information.
2.4 Parameter learning
In this part, we will derive the final loss function of the HAMN model and the
learning process of the corresponding parameters. In general, the loss function of
the HAMN model includes the loss of the extracted drug and the disease latent
factor and the loss between the predicted value and the target value.
The loss function of the extracted drug and disease latent factor are shown in
equations (9) and (10), which has been derived in 2.2.
LossOfDrugi = α ‖ sdrugi − sˆdrugi ‖2
+ (1− α) ‖ DrugSimi∗ − DˆrugSimi∗ ‖2
+ λ(
∑
l
‖Wl ‖2 + ‖ Vl ‖2) (9)
LossOfDiseasej = β ‖ sdiseasej − sˆdiseasej ‖2
+ (1− β) ‖ DiseaseSimj∗ − DˆiseaseSimj∗ ‖2
+ δ(
∑
d
‖Wd ‖2 + ‖ Vd ‖2) (10)
The loss between the predicted value and the target value is as shown in equation
(11), where rij represents the target value and rˆij is the predicted value derived
from the HAMN model.
LossOfPredictioni,j = rij log rˆij + (1− rij) log (1− rˆij) (11)
Hence, the final loss function of the HAMN model is shown in equation (12),
where R+ represents the positive sample set in which from known drug-disease
associations; R− represents the negative sample set, which can be obtained using
negative sampling techniques [22].
Loss =
∑
(i,j)∈R+∪R−
LossOfPredictioni,j + ϕLossOfDrugi
+ ψLossOfDiseasej (12)
The relevant parameters of the HAMN network can be learned by minimizing the
formula (12) by the SGD algorithm.
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As we can see from the above analysis, the model we propose has the following
advantages. First, at the section 2.1, the introduction of attention weight mechanism
enables the model to impose higher weight on similar drugs in neighbors, ensuring it
makes a greater contribution in the decision-making stage. Second, the introduction
of drugs-diseases auxiliary information can solve the cold start problem to a certain
extent at the section 2.2. Finally, the linear function is used to integrate the latent
factor and the neighborhood representation, so that the model has a holistic view
of the drugs-diseases interactions to infer the predicted value.
3. Results and discussion
This section systematically evaluates the performance of the HAMN model on two
real data sets and experimental comparisons with the most advanced algorithms
currently relevant. First, the two real data sets used in the experiment will be
introduced in detail in Section 3.1. Next, the evaluation criteria and calculation
methods used in the experiment will be introduced in Section 3.2. Then in section
3.3, we introduce the details and specific setting values of all hyperparameters in the
HAMN model, as well as the experimental analysis and discussion of two important
parameters. At the same time, in order to verify the effectiveness and superiority
of the HAMN model, the HAMN model is experimentally compared with several
currently relevant most advanced algorithms in section 3.4. To further verify the
practicability of the HAMN model, its performance in new drug scenarios will be
evaluated in Section 3.5.
3.1 Data set
This experiment uses two current mainstream data sets, Gottlieb dateset and
Cdataset [16] . Gottlieb dateset contains 593 drugs, 313 diseases and 1933 proven
drug-disease relationships. Cdataset contains 663 drugs, 409 diseases and 2,532
proven drug-disease relationships. See Table 1 and 2 for details. The drugs and
diseases contained in the above data sets were registered in DrugBank [23] and
Online Mendelian Inheritance in Man [24] respectively.
Table 1: Statistics of the Gottlieb dataset.
Dataset Drugs Diseases Interactions Sparsity
Gottlieb 593 313 1933 1.041× 10−2
Table 2: Statistics of the Cdataset.
Dataset Drugs Diseases Interactions Sparsity
Cdataset 663 409 2532 9.337× 10−3
Drug similarities are calculated on the basis of SMILES [25] using the Chemi-
cal Development Kit [26]. Pairwise drug resemblance and chemical structures are
referred to as their 2D chemical patterns Tanimoto score. MimMiner [27], which esti-
mates the degree of pairwise disease resemblance through text mining their medical
description data in the OMIM database, obtains the similarities between illnesses.
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3.2 Evaluation metrics
This experiment uses a ten-fold cross-validation technique. And the unverified
drug-disease relationship in the data set was taken as negative samples are placed
in the test set, and then the training set is used to learn the relevant parameters
of the model. The performance of the trained model on the test set is evaluated,
thereby achieving a 10-fold cross-validation and final performance evaluation.
In order to comprehensively evaluate the performance of the HAMN model, we
use AUC (Area Under Curve Area), AUPR (Area Under Precision-Recall Curve)
and HR (Hit Ratio) as the evaluation indicators. AUC is currently a mainstream
evaluation indicator, but for the category imbalance problem, the AUC indicator
cannot capture all the information of the model, and the true performance of the
model can be reflected in a more comprehensive way by adding the AUPR indicator.
At the same time, HR is the most popular evaluation indicator in the field of
recommendation systems, which can well reflect the performance of the model in
real demand scenarios. Combined with the above three evaluation indicators, the
performance of the HAMN model can be more fairly and comprehensively displayed.
3.3 Parameter settings
The two important parameters of the HAMN model are the dimension of the
memory unit cn and the balance parameter η . Since the memory cell cn vector stores
the characteristic information of the drug in the neighbor role, its size controls the
complexity and fitting ability of the neighborhood module of the HAMN model.
At the same time, the hyperparameters η balance the weight ratio of the latent
factor model and the neighborhood model in the final output. Appropriate values
can improve the performance of the model. Therefore, this section sets up two
related experiments to evaluate the performance of the HAMN model under different
dimensions of the memory cell vector cn and hyperparameters η .
All hyperparameters of the HAMN model are set based on their performance on
the validation set. The validation set is created based on [18]. For the dimension of
memory unit and the value of η, we use the grid search to find the optimal combina-
tion in the interval {2, 4, 6, 8, 10} and the interval {0.1, 0.3, 0.5, 0.7, 0.9}. Similarly,
α and β are all grid searched in the interval {0.1, 0.3, 0.5, 0.7, 0.9}. Besides, λ and δ
are all grid searched in the interval {0.1, 0.01, 0.001}. To reduce the computational
complexity, ϕ and ψ in equation (12) are set to 1 by default. Finally, the learning
rate of the model varies in the interval {0.0001, 0.001, 0.05, 0.01}, and the appropri-
ate learning rate enables the model to learn better parameters. Finally, we set α,
β, λ, δ, η and the dimension of the hidden feature and the memory unit dimension
to 0.7, 0.3, 0.001, 0.01, 0.7, 128 and 6 according to the performance of the model
on the validation set.
3.3.1 The dimension of external memory unit
The dimension of the memory unit cn is one of the important parameters of the
HAMN model, which controls the complexity of the neighborhood module of the
HAMN model and its learning ability. If the dimension setting is too large, the
model training time will increase exponentially and over-fitting will easily occur.
Conversely, setting the dimension too small will prevent the model from learning
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the structural information contained in some strong drug-disease associations, which
will affect the performance of the neighborhood module. Therefore, this experiment
is set up to observe the effect of different memory cell vector dimensions on the
performance of the HAMN model. In addition, the search interval of the dimension
of the memory unit is set to {2, 4, 6, 8, 10}, and the remaining hyperparameters are
set to the default values. The experimental data set uses the Gottlieb data set and
Cdataset, the evaluation index uses the AUC value.
Figure 2(a) shows the impact of different memory unit dimensions on the perfor-
mance of the HAMN model. The abscissa of the graph represents the dimensions
of the memory unit and the ordinate is the AUC value. The experimental results
show that the performance of the model improves steadily with the increase of the
dimension of the memory unit. When the dimension is 6, the performance of the
model reaches its peak, and the AUC value is 0.946 and 0.958 at that point. How-
ever, followed by a degradation potentially due to overfitting and the model’s AUC
value begins to decrease.
By analyzing the above experimental results, it can be concluded that the appro-
priate memory unit dimension can enhance the fitting ability of the HAMN model
neighborhood module, and learn the structural information of strong drug-disease
correlation, thereby further improving the overall performance of the HAMN model.
(a)
(b)
Figure 2: (a)The effect of the dimensions of the external memory unit vector on the
HAMN model. (b)The effect of hyperparameters η on HAMN model.
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3.3.2 The weight value of η
The hyperparameter η controls the weight ratio of the latent factor module and
the neighborhood module in the final output. Appropriate values are crucial to the
performance of the HAMN model. Therefore, the following experiments are set up
to observe the effect of different values on the performance of the HAMN model.
In addition, the search interval of η values is set to {0.1, 0.3, 0.5, 0.7, 0.9}, and the
remaining hyperparameters are set to the default values. The experimental data set
and evaluation indicators are consistent with Section 3.3.1.
The experimental results in Figure 2(b) show that as the value of the hyperparam-
eter η increases continuously, the performance of the HAMN model behaves a stable
linear improvement. The above experimental results show that the importance of
the hidden feature module is higher than that of the neighborhood module, and it
should be given higher weight. However, the neighborhood model can accurately
judge part of the test set samples and the hidden feature module cannot accurately
predict the part of the samples. Hence, the neighborhood model should be given
partial weights so that the final predicted value takes into account the contribution
of the neighborhood module. Therefore, when the value is set to 0.7, the predic-
tion effect and generalization performance of the HAMN model are improved to a
certain extent.
3.4 Method comparison
We compare the HAMN model with several current mainstream algorithms, in-
cluding the latent factor based methods and the neighborhood based methods.
HAMNOAI: which is the model of HAMN without auxiliary information. The
drug similarity and disease similarity in the HAMN model are set to 0 to invalidate
the auxiliary information, and to obtain the HAMNOAI model.
ANMF [18]: The ANMF model is a neural matrix decomposition model, which is
a HAMN model without neighborhood information essentially.
BNNR [17]: The BNNR model is one of the latest research achievements in the
field of computational drug relocation, and its essence is a model based on hidden
features. In order to balance the calculation error between the similarity between
drugs and the similarity between diseases, it incorporates the regularization of nu-
clear specifications into the matrix decomposition model, which can effectively solve
the problem of overfitting and improve the prediction accuracy of the model.
DRRS [16]: The DRRS model is a mainstream latent factor model, which uses
drug-disease relationships matrix, drug similarity matrix and disease similarity ma-
trix to generate a hybrid matrix, and then uses the SVT algorithm to matrix de-
compose to generate predicted values.
HGBI [12]: HGBI is a classic neighborhood based method. HGBI is introduced
based on the guilt-by-association principle, as an intuitive interpretation of infor-
mation flow on the heterogeneous graph.
The parameters of the above comparison method are provided by their corre-
sponding documents.
Table 3 and Table 4 ist the experimental results of the above model on the two
published data sets. No matter indicators we use, AUC, other comparison methods.
In terms of AUC value, the HAMN model achieved the highest value of 0.946 on
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the Gottlieb dataset, which was higher than the 0.938 in ANMF model, 0.94 in the
HAMNOAI model, 0.932 in BNNR, 0.93 in the DRRS model and 0.829 in the HGBI
model. The HAMN model also gets the highest value of 0.958 on the Cdataset.
In terms of AUPR value, the HAMN model achieved the highest value of 0.385
on the Gottlieb dataset, which was higher than 0.347 in the ANMF model, 0.366
in the HAMNOAI model,0.315 in the BNNR model, 0.292 in the DRRS model and
0.16 in the HGBI model. The HAMN model also gets the highest value of 0.426 on
the Cdataset.
In terms of HR value, the HAMN model achieved the highest value on both
Gottlieb dataset and Cdataset. In the HR@10 scenario, the HAMN model achieved
the highest value of 76.2% in the Gottlieb dataset, which was higher than 74.2%
of the ANMF model, 75.1% of the HAMNOAI model, 75.9% of the BNNR model
,72.7% of the DRRS model and 59.3% of the HGBI model. The HAMN model also
gets the highest value of 79.1% on the Cdataset.
Table 3: Prediction results of different methods on Gottlieb dataset.
Method Name AUC AUPR HR@1 HR@5 HR@10
HAMN 0.946 0.385 51.5% 66% 76.3%
HAMNOAI 0.94 0.366 48.5% 63.7% 75.1%
ANMF 0.938 0.347 47.9% 61.3% 74.2%
BNNR 0.932 0.315 50.2% 64.7% 75.9%
DRRS 0.93 0.292 45.9% 53.1% 72.7%
HGBI 0.829 0.16 33% 45.4% 59.3%
Table 4: Prediction results of different methods on Cdataset.
Method Name AUC AUPR HR@1 HR@5 HR@10
HAMN 0.958 0.426 43.8% 67.2% 79.1%
HAMNOAI 0.954 0.407 42.9% 66.1% 77.6%
ANMF 0.952 0.394 42.1% 65.1% 76.3%
BNNR 0.948 0.388 42.9% 66.1% 78.2%
DRRS 0.947 0.351 32.3% 59% 70.1%
HGBI 0.858 0.204 26.7% 37.1% 55.1%
According to the above experimental results, the HAMN model performs better
than the neighborhood based model HGBI and the latent factor based model BNNR,
DRRS and ANMF, which reveals the effectiveness of combining the two CF models
into a single hybrid model. It is worth noting that the HAMN model is superior to
the ANMF model, the latter is essentially a HAMN model without neighborhood
information. It reveals that the integration of neighborhood information improves
the performance of the HAMN model to a certain extent.
3.5 The new drug scenario
The new drug scenario means to predict potential target for drug without previ-
ously known disease associations, which is more in line with the actual needs of the
real world. There are 171 drugs in the Gottlieb dataset associated with only one
known disease, and 177 drugs in the Cdataset associated with only one known dis-
ease. We removed drugs with one known association from the data set and placed it
in the test set. The remaining drug-disease associations were used as training sets,
and the model was trained and tested according to the above. The experimental
parameters are set according to the rules in Section 3.3. See section 3.3 for details.
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Table 5 and Table 6 list the experimental results of the above models on the
Gottlieb dataset and Cdataset. No matter indicators we use, AUC, AUPR or HR
metric, the HAMN model we propose performs better than other comparison meth-
ods. In terms of AUC value, the HAMN model achieved the highest value of 0.881
on the Gottlieb dataset, which was higher than the 0.859 in ANMF model, 0.865
in the HAMNOAI model, 0.83 in the BNNR model, 0.824 in the DRRS model and
0.746 in the HGBI model. The HAMN model also gets the highest value of 0.869
on the Cdataset.
Table 5: Prediction results of different methods for new drug on Gottlieb dataset.
Method Name AUC AUPR HR@1 HR@5 HR@10
HAMN 0.881 0.193 30.4% 36.6% 49.7%
HAMNOAI 0.865 0.176 28.9% 35.9% 47.3%
ANMF 0.859 0.161 28.1% 34.5% 46.2%
BNNR 0.83 0.142 28.7% 35.1% 47.3%
DRRS 0.824 0.107 28.1% 30.4% 39.2%
HGBI 0.746 0.065 9% 14% 24.6%
Table 6: Prediction results of different methods for new drug on Cdataset.
Method Name AUC AUPR HR@1 HR@5 HR@10
HAMN 0.869 0.113 26% 35% 39.5%
HAMNOAI 0.861 0.102 22.8% 34.1% 38.2%
ANMF 0.857 0.097 19.2% 33.3% 37.3%
BNNR 0.837 0.091 25.4% 33.9% 38.4%
DRRS 0.824 0.084 25.4% 30.5% 35%
HGBI 0.732 0.022 11.3% 21.5% 26%
In terms of AUPR values, the HAMN model achieved the highest value of 0.193
on the Gottlieb dataset, which was higher than 0.161 for the ANMF model, 0.176
for the HAMNOAI model, 0.142 for the BNNR, 0.107 for the DRRS model and
0.065 for the HGBI model. In addition, the HAMN model gets the highest value of
0.113 on the Cdataset.
In terms of HR value, HAMN’s value of HR@1 is smaller than the DRRS model
on Cdataset. The possible reason is the sparseness of the data set. However, in
the case of HR@5, HR@10 The HAMN model has achieved the highest value. In
the HR@10 scenario, the HAMN model achieved the highest value of 49.1% on
the Gottlieb dataset, which was higher than the 46.2% in ANMF model, 47.3% in
the HAMNOAI model, 47.3% in the BNNR model, 39.2% in the DRRS model and
24.6% of the HGBI model. Moreover, HAMN model achieves the maximum value
of 39.5% on Cdataset.
Due to the sparse data and cold start problems, new drug scenarios have always
been a major difficulty in the field of computing drug relocation. Moreover, the new
drug scene is more in line with the needs of the real world, making more and more
researchers committed to solving this problem. Different from previous models that
only use sparse historical drug-disease association, the HAMN model also introduces
similarity between drugs, similarity between diseases and structural information
contained in some strong correlations, which can alleviate the cold start problem.
The above experimental results show that the proposed HAMN model can alleviate
the cold start problem to some extent due to the inclusion of auxiliary information
and neighbor information. Therefore, the HAMN model can be applied to new drug
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scenarios. In addition, by comparing with the HAMNOAI model, which can be
regarded as a HAMN model without auxiliary information version. The HAMN
model is superior to the HAMNOAI model under all evaluation index, and it can
be concluded that the fusion of auxiliary information can be relieved the problem
of cold start to some extent, thereby improving the learning ability and prediction
effect of the model.
Through the experimental results on two mainstream data sets in the real world,
the HAMN model has outperformed the most advanced algorithms in the indicators
AUC, AUPR and HR. For the Gottlieb data set, the AUC, AUPR, and HR values
were 0.946, 0.385, and 76.2% respectively. The prediction performance of the model
for Cdataset is 0.958, the AUPR value is 0.426, and the HR value is 79.1%. The
validity and superiority of the HAMN model are verified to some extent by the fact
that the above results are better than the comparison mainstream algorithms.
Next by comparing with the ANMF model, which can be regarded as a HAMN
model without neighborhood information essentially. It can be concluded that the
fusion of neighborhood based approaches can improve the performance of the algo-
rithm to a certain extent by means of the fact that the HAMN model is superior
to the ANMF model under all evaluation index. Finally, by comparing with the
HAMNOAI model, which can be regarded as a HAMN model without auxiliary in-
formation version. Through the experimental results the HAMN model is superior
to the HAMNOAI model under all evaluation index, it can be concluded that the
fusion of auxiliary information can be relieved the problem of cold start to some
extent, which can improve the learning ability and prediction effect of the model.
4.Conclusion
Computational drug repositioning, which aims to find new applications for exist-
ing drugs, is gaining more attention from the pharmaceutical companies due to its
low attrition rate, reduced cost, and shorter timelines for novel drug discovery. In
this work, we developed a novel network architecture HAMN for drug reposition-
ing. HAMN model, which uses a memory network to combine the neighborhood
based approaches with latent factor based models in a nonlinear manner, and in-
corporates drug-disease auxiliary information to alleviate the cold start problem.
Experimental results on two real data sets show that our proposed HAMN model is
superior to other state of art methods. In future works, we will delve into the use of
multi-source data to calculate the similarity between drugs and diseases and more
types of latent factor models or neighborhood based approaches to further improve
the performance of the model.
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